

## Triglyceride/high-density lipoprotein cholesterol (TG/HDL-C) index as a reference criterion of risk for metabolic syndrome (MetS) and low insulin sensitivity in apparently healthy subjects

Blanca Guadalupe Baez-Duarte<sup>1\*</sup>, Irma Zamora-Gínez<sup>1</sup>, Ramiro González-Duarte<sup>2</sup>, Enrique Torres-Rasgado<sup>1</sup>, Guadalupe Ruiz-Vivanco<sup>1</sup>, Ricardo Pérez-Fuentes<sup>1,3</sup> and The Multidisciplinary Research Group Of Diabetes

<sup>1</sup>Faculty of Medicine, Benemérita Universidad Autónoma de Puebla (BUAP), Puebla, Pue.; <sup>2</sup>Faculty of Medicine, UNAM, Mexico City; <sup>3</sup>Centro de Investigación Biomédica de Oriente (CIBIOR), IMSS, Atlixco, Puebla, Pue. Mexico

### Abstract

**Aim:** To evaluate if the TG/HDL-C index can be considered as a reference criterion of MetS and low insulin sensitivity in apparently healthy subjects. **Methods:** The subjects were Mexican mestizos who resided in Puebla City, Mexico, who were anthropometrically, biochemically, and clinically characterized. The TG/HDL-C index was calculated by dividing triglyceride (TG) levels by HDL-C levels. MetS was diagnosed by the Third Report from the Adult Treatment Panel-National Cholesterol Education Program (ATP-III NCEP) criteria, while insulin sensitivity was evaluated by the Quantitative Insulin sensitivity Check Index (QUICKI). **Results:** The study included 813 subjects, with an average age of  $38.6 \pm 12.1$  years, of which 564 were women and 249 men. An association was found between high TG/HDL-C index and low insulin sensitivity (Odds ratio [OR]: 4.09;  $p < 0.01$ ) and with MetS (OR: 15.29;  $p < 0.01$ ). A correlation was found between the TG/HDL-C index and QUICKI ( $\rho$ : -0.4989;  $p < 0.01$ ) and with MetS ( $\rho$ : 0.6581;  $p < 0.01$ ). **Conclusion:** The results indicate that the TG/HDL-C index is associated with low insulin sensitivity and MetS in apparently healthy subjects, suggesting this index as a reference criterion of risk for low insulin sensitivity and MetS. (Gac Med Mex. 2017;153:152-8)

**Corresponding author:** Blanca Guadalupe Baez-Duarte, [blanquis121280@yahoo.com.mx](mailto:blanquis121280@yahoo.com.mx)

**KEY WORDS:** Metabolic syndrome. QUICKI. Cardiovascular risk. Insulin sensitivity. TG/HDL-C index.

### Resumen

**Propósito:** Evaluar si el índice TG/HDL-C puede ser considerado como un criterio de riesgo para SMet y baja SI en sujetos aparentemente sanos. **Métodos:** Los sujetos participantes fueron caracterizados clínica, antropométrica y bioquímicamente. El índice TG/HDL-C se calculó dividiendo los valores de los TG entre los valores del HDL-C. El SMet se diagnosticó mediante los criterios establecidos por el Tercer Reporte del Panel de Tratamiento para Adultos del Programa Nacional de Educación en Colesterol (ATP-III NCEP) de los EE.UU. La SI se evaluó mediante el índice cuantitativo de evaluación de la SI (QUICKI, Quantitative Insulin Sensitivity Check Index). **Resultados:** En el estudio participaron 813 sujetos, de los cuales 564 eran

#### Correspondence to:

\*Blanca Guadalupe Baez-Duarte  
Benemérita Universidad Autónoma de Puebla  
Av. 13 Sur, 2702  
Col. Volcanes  
C.P. 72410, Puebla, Pue., México  
E-mail: [blanquis121280@yahoo.com.mx](mailto:blanquis121280@yahoo.com.mx)

Fecha de recepción: 22-11-2015  
Fecha de aceptación: 13-12-2015

mujeres y 249 eran hombres. Se encontró asociación entre el TG/HDL-C alto y la SI (razón de momios [RM]: 4.09;  $p < 0.01$ ) y con el SMet (RM: 15.29;  $p < 0.01$ ). Se encontró correlación entre el índice TG/HDL-C y el QUICKI ( $\rho$ : -0.4989;  $p < 0.01$ ) y con el SMet ( $\rho$ : 0.6581;  $p < 0.01$ ). **Conclusión:** Los resultados muestran una buena correlación y asociación entre el índice TG/HDL-C y el SMet y con la SI, sugiriendo a este índice como un criterio de riesgo para SMet y SI baja.

**PALABRAS CLAVE:** Síndrome metabólico. QUICKI. Riesgo Cardiovascular. Sensibilidad a la insulina. Índice TG/HDL-C.

## Introduction

The MetS involves a cluster of metabolic abnormalities including centrally distributed obesity, decreased concentration of high-density lipoprotein cholesterol (HDL-C), elevated triglycerides (TG), high blood pressure, and hyperglycemia<sup>1</sup>. MetS is also a risk factor for developing type 2 diabetes mellitus (DM2), ischemic heart disease, and arteriosclerosis-associated stroke, which are causes of mortality<sup>1,2</sup>. Given the previously mentioned information, MetS is considered a public health problem worldwide, especially in Westernized countries<sup>1</sup>, presenting a prevalence of 39.7% in Mexico<sup>3,4</sup>.

Recent studies have suggested that MetS might be the result of different, but interrelated, pathophysiological mechanisms such as endothelial dysfunction, low-intensity inflammatory process, visceral obesity, oxidative stress, genetic factors, and alterations in insulin sensitivity<sup>2,5,6</sup>.

Insulin sensitivity can be defined as the responsiveness to the metabolic actions of insulin, as determined by both genetic and environmental factors, and plays an important pathophysiological role in diabetes<sup>7</sup>.

When insulin sensitivity is impaired, compensatory hyperinsulinemia is produced, which generates, in the long term, a pancreas beta cell dysfunction, promoting the development of DM2<sup>8</sup>. During this period, diverse metabolic changes increase the risk of cardiovascular disease<sup>8</sup>.

Insulin sensitivity can be determined by various methods. One of these is the hyperinsulinemic-euglycemic (HIE) glucose clamp technique that is the "gold standard" for quantifying insulin sensitivity *in vivo*, but none of these have been easily implemented in large studies<sup>7</sup>.

Instead of the HIE glucose clamp technique, a Quantitative Insulin sensitivity Check Index (QUICKI =  $1/[\log \text{fasting insulin} + \log \text{fasting glucose}]$ ) was defined, which has substantially good correlation with the HIE glucose clamp technique<sup>7,9</sup>. QUICKI is obtained from fasting blood samples and may be useful for clinical research because it can be used for easy and accurate estimation of insulin sensitivity in subjects at risk. QUICKI has been validated extensively against the reference

standard glucose clamp method<sup>7,10-12</sup> and comprises a simple, robust, accurate, and reproducible method that appropriately predicts changes in insulin sensitivity<sup>13</sup>.

In a previous study, we detected a decrease in insulin sensitivity (measured by QUICKI) in subjects with metabolic imbalance without MetS and a progressive deterioration of insulin sensitivity in subjects with MetS as the number of features of MetS increased<sup>14</sup>. We suggested that assessment of insulin sensitivity in subjects with a metabolic imbalance might detect early stages of metabolic abnormalities (the pre-metabolic syndrome phase) that characterize MetS, not only detecting it at an early stage, but also enabling prevention strategies<sup>14</sup>.

As mentioned previously, MetS is a risk factor for cardiovascular diseases<sup>1,2</sup>. In this context, a new index has been proposed to estimate cardiovascular risk, which considers the TG/HDL-C ratio. This index has been utilized in different types of populations, such as in subjects at high risk for coronary disease<sup>15</sup>, in subjects with DM2<sup>16</sup>, and in patients with coronary artery disease<sup>17</sup>; in all of these studies, the TG/HDL-C index was an independent predictor of cardiovascular disease. In a study conducted in Mexican obese subjects, we found that the TG/HDL-C index was higher in overweight and obese subjects compared with healthy subjects<sup>18</sup>.

Taking this information into account, we assessed whether the TG/HDL-C index may serve as a reference criterion of risk for low insulin sensitivity and MetS, managing to detect individuals at risk at an early stage, where one of the targets for clinical practice is to facilitate the application of criteria for early disease detection and to provide the cut-off point for their application in patients.

## Materials and methods

### Subjects and setting

A total of 875 Mexican subjects (Central Mexico) participated in the study. Subjects with an incomplete clinical history or who had ongoing chronic inflammatory (arthritis, rhinitis, and trauma), endocrine (hyperthyroidism and hypothyroidism), or any chronic disease (except hypertension and hyperlipidemia) were excluded

from the study. Use of medications, alternative treatments, smoking, and alcoholism were also considered exclusion criteria, as well as subjects with a previous diagnosis of DM2. The 813 subjects who met the selection criteria had an average age of  $38.6 \pm 12.1$  years; 564 were women (who were not pregnant or breastfeeding) and 249 men. The subjects of the present study were Mexican mestizos who resided in Puebla City, Mexico.

The study was approved by the Scientific Research and Ethics Committee of the Instituto Mexicano del Seguro Social (IMSS) and informed consent was obtained from all individual participants included in the study.

### Clinical characterization

Anthropometric measurements such as height, weight, and percentage of body fat (%BF) were determined using an electronic digital scale (Tanita® Body Composition Analyzer, Model TBF-215; Tokyo, Japan); scale capacity, 200 kg. Waist circumference (WC) was measured at the midpoint between the highest point of the iliac crest and the lowest point of the costal margin at the mid-axillary line, employing a non-stretching anthropometric measuring tape. Body mass index (BMI) was calculated using the Quetelet BMI formula. Subjects without overweight or obesity were considered if BMI was  $< 25 \text{ kg/m}^2$  and with overweight or obesity if their BMI was  $\geq 25 \text{ kg/m}^2$ <sup>19</sup>. Blood pressure was determined in a sitting position and after five minutes of rest according to the Mexican Official Standard<sup>20</sup> for the prevention, treatment, and control of hypertension, using a Baumanometer® (Microlife AG, Heerbrugg, Switzerland) and a stethoscope (3M Littmann® Classic II; Neuss, Germany).

### Biochemical characterization

Following an overnight fast (10-12 hours) by the study participants, blood samples were obtained by venipuncture. Fasting glucose, fasting insulin, total cholesterol (TC), TG, HDL-C, and glucose levels of the oral tolerance test (GlcOTT), determined two hours after a 75 g glucose load, were measured according to conventional laboratory protocols using the periodic endpoint method. Plasma glucose levels and lipid profile were determined using the Synchron CX5 Analyzer System (Beckman Coulter, Fullerton, CA, USA). Insulin concentration was determined by chemiluminescence in an immunoassay utilizing anti-insulin mouse monoclonal antibodies with alkaline phosphatase (Beckman Coulter Access System).

Insulin sensitivity was calculated according to the Quantitative Insulin sensitivity Check Index (QUICKI) with the following formula:  $\text{QUICKI} = 1/(\log \text{fasting insulin} + \log \text{fasting glucose mg/dl})^7$ ; values  $< 0.357$  are representative of low insulin sensitivity, based on a report by Hrebíček, et al.<sup>21</sup>.

According to the cut-off point established<sup>22</sup> for diagnosis of glucose intolerance and DM2, subjects were detected with new-onset DM2 or glucose intolerance.

Normal values of TC levels  $< 200 \text{ mg/dl}$ , TG levels  $< 150 \text{ mg/dl}$ , and HDL-C levels  $\geq 40 \text{ mg/dl}$  were considered according to the Third Report from the Adult Treatment Panel (ATP III) of the National Cholesterol Education Program (NCEP) criteria<sup>23</sup>. Low-density lipoprotein cholesterol (LDL-C) was determined using the formula cited in Mexican Norm NOM-037-SSA2-2012 for the prevention, treatment, and control of dyslipidemia<sup>24</sup> in which very low-density lipoprotein cholesterol (VLDL-C) =  $\text{TG}/5$  and  $\text{LDL-C} = \text{TC} - (\text{VLDL-C} + \text{HDL-C})$ .

**Table 1. Anthropometrical and biochemical variables of study subjects**

	Study subjects (n = 813)
BMI (kg/m <sup>2</sup> )	27.8 ± 5.3
WC M (cm)	96.1 ± 13.2
WC W (cm)	91.5 ± 12.1
BF M (%)	25.3 ± 8.0
BF W (%)	34.8 ± 7.2*
Fasting glucose (mg/dl)	93.1 ± 11.2
GlcOTT (mg/dl)	114.1 ± 28.8
Fasting insulin (μU/ml)	10.2 ± 7.7
QUICKI	0.348 ± 0.034
TG (mg/dl)	163.1 ± 105.6
TC (mg/dl)	187.5 ± 43.1
HDL-C M (mg/dl)	36.8 ± 12.9
HDL-C W (mg/dl)	43.0 ± 15.1
LDL-C (mg/dl)	116.2 ± 34.9
VLDL-C (mg/dl)	30.1 ± 18.4
TG/HDL-C index	4.2 ± 3.7

Results were expressed as means ± standard deviation (SD). \*P ≤ 0.05, two-tailed Student t test, statistically significant differences between men and women. BMI: body mass index; WC: waist circumference; M: Men; W: women; BF: body fat; GlcOTT: glucose levels of the oral tolerance test; QUICKI: Quantitative Insulin sensitivity Check Index; TG: triglycerides; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; VLDL-C: very low-density lipoprotein cholesterol.

The TG/HDL-C index was calculated by dividing the concentration of TG by HDL-C. The cut-off point for cardiovascular risk was TG/HDL-C > 3<sup>16,25</sup>.

MetS was defined according to ATP III-NCEP criteria<sup>23</sup> with WC values adjusted to the Mexican population (NCEP-ATP III<sup>m</sup>)<sup>14</sup>. Diagnosis of MetS was established if three or more of the following risk factors were present: blood pressure ≥ 130/85 mmHg; fasting glucose ≥ 100 mg/dl; TG ≥ 150 mg/dl; HDL-C < 40 mg/dl in males and < 50 mg/dl in females; and WC ≥ 90 cm in males and ≥ 80 cm in females.

**Statistical analysis**

The Kurtosis Normality of Residuals test was employed to determine normality of data distribution. Continuous variables with normality and equal variances were analyzed utilizing the Student *t* test. When not normality, but equal variances were observed, a Kruskal-Wallis test was employed. Nonparametric continuous variables were analyzed using the Mann-Whitney *U* test and, to establish an association between the variables, we utilized multinomial logistic regression. Correlation analysis was carried out using the Spearman rank test. Data were analyzed with SPSS software (v. 21.0 for Windows; SPSS, Inc., Chicago, IL, USA). Differences between groups were considered significant at *p* < 0.05.

**Results**

In the study, 813 subjects participated who had an average age of 38.6 ± 12.1 years, among whom 564 were women and 249 men. Of all of the participating subjects, 69.86% were overweight or obese in accordance with the BMI determined; women had a higher percentage of body fat compared with men (Table 1). In all, 247 subjects had glucose intolerance and both males and females had, on average, low levels of HDL-C and high levels of TG (Table 1).

Diastolic and systolic blood pressure averages apparently fell within the normal range (110.2 ± 14.2 and 72.8 ± 9.8 mmHg, respectively); however, 145 subjects presented blood pressure above the range recommended by ATP-III NCEP (130/85 mmHg)<sup>23</sup>.

We identified 518 subjects who had low insulin sensitivity. The group of subjects with low insulin sensitivity had a higher average WC as well as higher levels of glucose, insulin, and TG/HDL-C index compared with the group of subjects with normal insulin sensitivity; 68.4% of subjects with low insulin sensitivity had high cardiovascular risk (Table 2).

There were 362 subjects with a diagnosis of MetS and 451 without a diagnosis of MetS; however, of these 451 subjects, 358 had one or two diagnostic criteria for MetS. A total of 76.5% of subjects with MetS had a high TG/HDL-C index (Table 3).

**Table 2. Anthropometrical and biochemical characteristics of the study subjects divided by insulin sensitivity**

	Study groups	
	Normal insulin sensitivity (n = 295)	Low insulin sensitivity (n = 518)
Age (years)	36.8 ± 12.0	39.6 ± 11.9*
Gender (M/W)	84/211	165/353
BMI (kg/m <sup>2</sup> )	25.2 ± 3.9	29.3 ± 5.5*
WC (cm)	86.2 ± 9.9	96.8 ± 12.4*
Fasting glucose (mg/dl)	87.6 ± 9.0	96.2 ± 11.2*
GlcOTT (mg/dl)	101.3 ± 23.8	122.4 ± 28.8*
Fasting insulin (µU/ml)	5.0 ± 1.4	13.3 ± 8.2*
QUICKI	0.384 ± 0.025	0.328 ± 0.019*
TG/HDL-C index	2.5 ± 1.6	5.1 ± 4.3*
%S CVR	28.7	68.4

Results were expressed as means ± standard deviation (SD). \**P* ≤ 0.05 Mann-Whitney *U* test  
M: men; W: women; BMI: body mass index; WC: waist circumference; GlcOTT: glucose levels of the oral tolerance test; QUICKI: Quantitative Insulin sensitivity Check Index;  
TG: triglycerides; HDL-C, high-density lipoprotein cholesterol; %S CVR: percentage of subjects with cardiovascular risk.

**Table 3. Anthropometrical and biochemical characteristics of the study subjects divided by metabolic syndrome**

	Study groups	
	Without MetS (n = 451)	With MetS (n = 362)
Age (years)	36.1 ± 12.1	41.6 ± 11.3*
Gender (M/W)	126/325	123/239
BMI (kg/m <sup>2</sup> )	25.9 ± 4.5	30.1 ± 5.3*
WC (cm)	87.9 ± 11.4	99.2 ± 11.2*
Fasting glucose (mg/dl)	88.7 ± 9.0	98.5 ± 11.4*
GlcOTT (mg/dl)	103.9 ± 23.9	126.7 ± 29.4*
Fasting insulin (μU/ml)	7.8 ± 5.0	13.2 ± 9.2*
QUICKI	0.363 ± 0.03	0.330 ± 0.03*
TG/HDL-C index	2.5 ± 1.4	6.4 ± 4.6*
%S CVR	26.8	76.5

Results were expressed as means ± standard deviation (SD). \*P ≤ 0.05 Mann-Whitney U test.

MetS: metabolic syndrome; M: men; W: women; BMI: body mass index; WC: waist circumference; GlcOTT: glucose levels of the oral tolerance test; QUICKI: Quantitative Insulin sensitivity Check Index; TG: triglycerides; HDL-C: high-density lipoprotein cholesterol; %S CVR: percentage of subjects with cardiovascular risk.

We found in this study a statistical association between cardiovascular risk and insulin sensitivity (odds ratio [OR]: 4.09;  $p < 0.01$ ; adjusted by age, gender, and WC) and with MetS (OR: 15.29;  $p < 0.01$ , adjusted by age, gender, and WC). We found a correlation between the TG/HDL-C index and QUICKI ( $\rho$ : -0.4989;  $p < 0.01$ ), and between the TG/HDL-C index and MetS ( $\rho$ : 0.6581;  $p < 0.01$ ).

## Discussion

In this study, despite our study population being one of apparently healthy subjects, we found that they had metabolic disorders that condition the development of cardiovascular disease and DM2. Proof of this includes low insulin sensitivity and the high TG/HDL-C index found in the subjects. This is in agreement with our previous studies conducted in subjects with MetS<sup>14,26</sup> and in obese subjects<sup>18</sup>, in which subjects with metabolic disorders had decreased insulin sensitivity and increased cardiovascular risk compared with healthy subjects. In all of these studies, the behavior of these two indices (QUICKI and TG/HDL-C index) was similar, which leads us to suggest that both of the indices independently may comprise reference criteria for the early metabolic alterations that are widely related with MetS. QUICKI was previously proposed as a risk marker for the development of MetS<sup>14</sup>. In the present study, we suggest the TG/HDL-C index as an additional and useful

reference criterion of risk for MetS, providing the opportunity to have a criterion for indicating risk for developing both MetS and low insulin sensitivity. This is important, considering that this index requires simple calculation (its equation is a simple one) for application.

On the other hand, the cut-off point of the TG/HDL-C index of  $> 3$  for cardiovascular risk strongly correlated with diagnosis of MetS and insulin sensitivity, and a strong association with these two variables is also demonstrated. This cut-off point has been employed in other studies<sup>16,25</sup>.

The application of this TG/HDL-C index to detect subjects at risk for MetS is simple, and the obtaining of its components (TG and HDL-C) lies within routine testing at the majority of hospitals. The use of this index might avoid indiscriminate utilization of laboratory tests, as well as related expenditures<sup>27</sup>.

The TG/HDL-C index has been advocated as a simple clinical indicator of cardiovascular disease, estimating atherogenic small dense LDL-C particles and predicting arterial stiffness and acute cardiovascular events in adults with DM2<sup>16</sup> and healthy subjects without diabetes<sup>28</sup>, which has been demonstrated in different studies. Furthermore, the TG/HDL-C index has been described as an independent determinant of arterial stiffness in adolescents and young adults, especially in obese youths, suggesting that the use of the TG/HDL-C index may also be helpful in identifying

young adults requiring aggressive intervention to prevent atherosclerotic cardiovascular disease<sup>29</sup>.

Although there are diverse studies that support the TG/HDL-C index as reference criteria of cardiovascular risk, there are, to our knowledge, no studies that have reported the relationship with MetS or insulin sensitivity (measured by QUICKI).

Within this context, there are two studies conducted in Mexican population. One of these examined the clinical usefulness of the TG/HDL-C index and MetS in healthy college students (17-24 years of age) of Mexican mestizo ancestry to identify insulin resistance and increased cardiometabolic risk. These authors concluded that both a higher TG/HDL-C index and a diagnosis of MetS identified young insulin-resistant individuals with an increased cardiometabolic risk profile. It is noteworthy that the authors reported no association between the TG/HDL-C index and MetS<sup>30</sup>.

The other study conducted in a Mexican population showed an elevated TG/HDL-C index detected in 61.3% of subjects with insulin resistance and an association between these two variables with an OR of 2.64<sup>25</sup>.

We found a strong correlation between the TG/HDL-C index and insulin sensitivity (measured by QUICKI), and also with MetS, both reported, to our knowledge, for the first time. Together with this, we also found a strong association between these variables, respectively.

Detection of an elevated TG/HDL-C index will identify the onset of metabolic alterations related with MetS such as decreased insulin sensitivity and altered lipid profile. Thus, the initiation of appropriate treatment according to the therapeutic goals is recommended by different studies<sup>23,31</sup>.

The results of this study indicate that the TG/HDL-C index is associated with insulin sensitivity (measured by QUICKI) and with MetS in the studied subjects, allowing to suggest this index as an adequate reference criterion of risk for low insulin sensitivity and MetS, which might facilitate the detection of metabolic changes in early stages and avoid further complications.

## Declaration of interest

This study was supported by grants from the Consejo Nacional de Ciencia y Tecnología de México, SALUD 2004-01-023, Fundación IMSS, A.C., and from the Programa de Mejoramiento del Profesorado (PROMEP) as New Full-time Professor (NFTP) with folio number PTC-342, Agreement No. PROMEP/103.5/13/6823. BG-BD was supported by a fellowship from Consejo Nacional

de Ciencia y Tecnología (CONACyT) de México, CVU/ Fellow Number 165238. The authors declare that there is no conflict of interest that would prejudice the impartiality of this scientific work.

## Acknowledgments

The study was conducted at the Eastern Biomedical Research Center of the Instituto Mexicano del Seguro Social (CIBIOR, IMSS) in Puebla City, Mexico. We gratefully acknowledge the commitment and dedication of the Physicians, Chemists, Nurses, Nutritionists, and participating personnel in the Mexican Diabetes Prevention Study. Investigators of the Multidisciplinary Research Group on Diabetes of the Instituto Mexicano del Seguro Social participating in the Mexican Diabetes Prevention Study: Fernando Guerrero-Romero, MD, PhD, FACP; Martha Rodríguez-Morán, MD, MSc, PhD; Jorge Escobedo de la Peña, MD, MSc; Niels Wachter, MD, PhD; Adolfo Chávez-Negrete, MD, MSc, PhD; Cristina Revilla-Monsalve, MD, MSc, PhD; Esperanza Martínez-Abundis, MD, MSc, PhD; Javier E. García de Alba, MD, MSc, PhD; Manuel González-Ortíz, MD, MSc, PhD, and Sergio Islas-Andrade, MD, MSc, PhD, FACP.

## Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

## References

1. Zimmet P, Alberti GMM, Serrano-Rios M. [A new international diabetes federation worldwide definition of the metabolic syndrome: the rationale and the results]. *Rev Esp Cardiol*. 2005;58:1371-6.
2. García-García E, De la Llata-Romero M, Kaufer-Horwitz M, et al. [Obesity and the metabolic syndrome as a public health problem: a reflection]. *Salud Publica Mex*. 2008;50:530-47.
3. Córdova-Villalobos JA, Barriguete-Meléndez JA, Lara-Esqueda A, et al. Chronic non-communicable diseases in Mexico: epidemiologic synopsis and integral prevention. *Salud Publica Mex*. 2008;50:419-27.
4. Gutiérrez JP, Rivera-Dommarco J, Shamah-Levy T, et al. Encuesta Nacional de Salud y Nutrición 2012. Resultados Nacionales. Cuernavaca, Morelos, México: Instituto Nacional de Salud Pública (INSP, MX). 2012.
5. González-Chávez A, Simental L, Elizondo-Argueta S, Sánchez-Zúñiga J, Gutiérrez-Salgado G, Guerrero-Romero F. Prevalencia del síndrome metabólico entre adultos mexicanos no diabéticos, usando las definiciones de la OMS, NCEP-ATPIIIa e IDF. *Rev Med Hosp Gen Mex*. 2008;71:11-19.
6. González-Chávez A, Amancio-Chassin O, Islas-Andrade S, et al. [Cardiovascular risk factors associated to abdominal obesity in apparently healthy subjects]. *Rev Med Inst Mex Seguro Soc*. 2008;46:273-9.
7. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. *J Clin Endocrinol Metab*. 2000;85:2402-10.
8. Pineda CA. [Metabolic syndrome: definition, history, criteria]. *Colomb Med*. 2008;39:96-106.
9. Chen H, Sullivan G, Quon MJ. Assessing the predictive accuracy of QUICKI as a surrogate index for insulin sensitivity using a calibration model. *Diabetes*. 2005;54:1914-25.

10. Chen H, Sullivan G, Yue LQ, Katz A, Quon MJ. QUICKI is a useful index of insulin sensitivity in subjects with hypertension. *Am J Physiol Endocrinol Metab.* 2003;284:E804-12.
11. García-Cuartero B, García-Lacalle C, Jiménez-Lobo C, et al. [The HOMA and QUICKI indexes, and insulin and C-peptide levels in healthy children. Cut off points to identify metabolic syndrome in healthy children]. *An Pediatr (Barc).* 2007;66:481-90.
12. Sarafidis PA, Lasaridis AN, Nilsson PM, et al. Validity and reproducibility of HOMA-IR, 1/HOMA-IR, QUICKI and McAuley's indices in patients with hypertension and type II diabetes. Surrogates of insulin sensitivity in hypertension. *J Hum Hypertens.* 2007;21:709-16.
13. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance *in vivo*: advantages, limitations, and appropriate usage. *Am J Physiol Endocrinol Metab.* 2008;294:E15-26.
14. Baez-Duarte BG, Sánchez-Guillén MC, Pérez-Fuentes R, et al. B-cell function is associated with metabolic syndrome in Mexican subjects. *Diabetes Metab Syndr Obes.* 2010;3:1e9.
15. Da Luz PL, Favarato D, Faria-Neto JR Jr, Lemos P, Chagas AC. High ratio of triglycerides to HDL-cholesterol ratio predicts extensive coronary disease. *Clinics (Sao Paulo).* 2008;63:427-32.
16. Boizel R, Benhamou PY, Lardy B, Laporte F, Foulon T, Halimi S. Ratio of triglycerides to HDL cholesterol is an indicator of LDL particle size in patients with type 2 diabetes and normal HDL cholesterol levels. *Diabetes Care.* 2000;23:e1679-85.
17. Frohlich J, Dobiasova M. Fractional esterification rate of cholesterol and ratio of triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography. *Clin Chem.* 2003;49:1873-80.
18. Baez-Duarte BG, Zamora-Gínez I, Mendoza-Carrera F, et al. Serum levels of glutathione peroxidase 3 in overweight and obese subjects from Central Mexico. *Arch Med Res.* 2012;43:541-7.
19. ADA. Standards of Medical Care in Diabetes - 2014. *Diabetes Care.* 2014;37(Suppl 1):S14-80.
20. Mexican Ministry of Health. Amendment to Norma Oficial Mexicana NOM-030-SSA2-1999, for prevention, treatment and control of hypertension, to read as Norma Oficial Mexicana NOM-030-SSA2-2009 for the prevention, detection, diagnosis, treatment and control of systemic arterial hypertension. Mexico City, Mexico: Ministry of Health. 2009.
21. Hrebíček J, Janout V, Malincikova J, Horáková D, Cizek L. Detection of insulin resistance by simple quantitative insulin sensitivity check index QUICKI for epidemiological assessment and prevention. *J Clin Endocrinol Metab.* 2002;87:e144-7.
22. Mexican Ministry of Health. Norma Oficial Mexicana NOM-015-SSA2-2010 for prevention, treatment and control of diabetes mellitus. Mexico City, Mexico: Ministry of Health. 2010.
23. NCEP-ATPIII. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation.* 2002;106:e3143-421.
24. Mexican Ministry of Health. Norma Oficial Mexicana NOM-037-SSA2-2012 for prevention, treatment and control of dyslipidemia. Mexico City, Mexico: Mexican Ministry of Health. 2012.
25. González-Chávez A, Simental-Mendieta LE, Elizondo-Argueta S. Elevated triglycerides/HDL-cholesterol ratio associated with insulin resistance. *Cir Cir.* 2011;79:126-31.
26. Baez-Duarte BG, Mendoza-Carrera F, García-Zapién, et al. Glutathione Peroxidase 3 serum levels and GPX3 gene polymorphisms in subjects with metabolic syndrome. *Arch Med Res.* 2014;45:375-82.
27. Barba-Evía JR. [Inappropriate utilization of clinical laboratory]. *Rev Mex Patol Clin.* 2003;50:209-23.
28. Maruyama C, Imamura K, Teramoto T. Assessment of LDL particle size by triglyceride/HDL-cholesterol ratio in non-diabetic, healthy subjects without prominent hyperlipidemia. *J Atheroscler Thromb.* 2003;10:186-91.
29. Urbina EM, Khoury PR, McCoy CE, Dolan LM, Daniels SR, Kimball TR. Triglyceride to HDL-C ratio and increased arterial stiffness in children, adolescents and young adults. *Pediatrics.* 2013;131:e1082-90.
30. Murguía-Romero M, Jiménez-Flores JR, Sigris-Flores SC, et al. Plasma triglyceride/HDL-cholesterol ratio, insulin resistance, and cardiometabolic risk in young adults. *J Lipid Res.* 2013;54:2795-9.
31. Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. *Eur Heart J.* 2011;32:1345-61.